{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:16:17Z","timestamp":1759482977561},"reference-count":0,"publisher":"American Diabetes Association","issue":"11","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1990,11,1]]},"abstract":"<jats:p>Triflusal (2-acetoxy-4-trifluormethylbenzoic acid) is a platelet-antiaggregant drug that selectively inhibits thromboxane synthesis with little effect on prostacyclin production. In this study, we evaluated the effect of 5- day administration of 900 mg\/day triflusal on glomerular filtration rate (GFR), renal plasma flow (RPF), urinary albumin excretion (UAE), thromboxane B2 (TXB2), 6-ketoprostaglandin F1\u03b1 (PGF1\u03b1), and PGE2 in nine normotensive insulin-dependent diabetic patients with UAE between 30 and 103 fxg\/min. Plasma TXB, and plasma renin activity (PRA) were also determined. After administration of triflusal, we observed a reduction in microalbuminuria (59 \u00b1 25 vs. 33 \u00b1 22 \u03bcg\/min, P &amp;lt; 0.01), an increase in RPF (648 \u00b1 119 vs. 722 \u00b1 134 ml\u00b7 min\u22121 \u00b7 1.73 m\u22122, P &amp;lt; 0.01), and a reduction in filtration fraction (0.24 \u00b1 0.04 vs. 0.20 \u00b1 0.03, P &amp;lt; 0.01). Triflusal produced a significant reduction in both plasma TXB2 (130 \u00b1 39 vs. 52 \u00b1 32 pg\/ml, P &amp;lt; 0.02) and urine TXB2 (523 \u00b1 249 vs. 312 \u00b1 11 pg\/min, P &amp;lt; 0.02), without changes in PRA and UAE of 6-keto-PGF1\u03b1 and PGE2. Metabolic control and arterial blood pressure did not change during the study. These results suggest that platelet-antiaggregant therapy can reduce microalbuminuria in diabetic patients. This effect could be mediated by a reduction in the transglomerular hydraulic pressure through a vasodilation of efferent arterioles secondary to renal thromboxane synthesis inhibition.<\/jats:p>","DOI":"10.2337\/diacare.13.11.1114","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T22:51:27Z","timestamp":1173135087000},"page":"1114-1117","update-policy":"http:\/\/dx.doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":12,"title":["Effects of Thromboxane Synthesis Inhibitor Triflusal on Renal Hemodynamics in Microalbuminuric Diabetic Patients"],"prefix":"10.2337","volume":"13","author":[{"given":"Enric","family":"Esmatjes","sequence":"first","affiliation":[{"name":"Endocrinology and Diabetes Unit, Hormonal and Nuclear Medicine Laboratories, Hospital Clinic i Provincial, University of Barcelona\u2008Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus I","family":"Conget","sequence":"additional","affiliation":[{"name":"Endocrinology and Diabetes Unit, Hormonal and Nuclear Medicine Laboratories, Hospital Clinic i Provincial, University of Barcelona\u2008Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Gaya","sequence":"additional","affiliation":[{"name":"Endocrinology and Diabetes Unit, Hormonal and Nuclear Medicine Laboratories, Hospital Clinic i Provincial, University of Barcelona\u2008Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria R","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Endocrinology and Diabetes Unit, Hormonal and Nuclear Medicine Laboratories, Hospital Clinic i Provincial, University of Barcelona\u2008Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge P","family":"Ferrer","sequence":"additional","affiliation":[{"name":"Endocrinology and Diabetes Unit, Hormonal and Nuclear Medicine Laboratories, Hospital Clinic i Provincial, University of Barcelona\u2008Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Rivera","sequence":"additional","affiliation":[{"name":"Endocrinology and Diabetes Unit, Hormonal and Nuclear Medicine Laboratories, Hospital Clinic i Provincial, University of Barcelona\u2008Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enric","family":"Vilardell","sequence":"additional","affiliation":[{"name":"Endocrinology and Diabetes Unit, Hormonal and Nuclear Medicine Laboratories, Hospital Clinic i Provincial, University of Barcelona\u2008Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/13\/11\/1114\/440175\/13-11-1114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/13\/11\/1114\/440175\/13-11-1114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T23:26:56Z","timestamp":1647041216000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/13\/11\/1114\/1479\/Effects-of-Thromboxane-Synthesis-Inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,11,1]]},"references-count":0,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1990,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.13.11.1114","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,11,1]]}}}